Related Experiment Videos
Treatment of acute immune thrombocytopenic purpura
1University of Louisville School of Medicine, KY 40202, USA.
Insights
Diagnosing acute immune thrombocytopenic purpura (ITP) involves medical history, physical exams, and lab tests. Treatment options for ITP, including corticosteroids and IVIg, aim to prevent severe bleeding.
Area of Science:
- Hematology
- Immunology
- Pediatrics
Background:
- Acute immune thrombocytopenic purpura (ITP) is a bleeding disorder often preceded by viral infections in children.
- Diagnosis relies on medical history, physical examination revealing purpura, and complete blood cell count.
- Treatment decisions for acute ITP are debated, focusing on preventing critical complications like intracranial hemorrhage.
Purpose of the Study:
- To review diagnostic criteria for acute immune thrombocytopenic purpura (ITP).
- To discuss current treatment strategies and their associated benefits and drawbacks.
- To explore emerging immunomodulatory therapies for ITP management.
Main Methods:
- Review of medical literature on acute immune thrombocytopenic purpura (ITP) diagnosis and treatment.
- Analysis of diagnostic methods including patient history, physical examination, and laboratory testing.
- Evaluation of therapeutic options such as corticosteroids, intravenous immunoglobulin (IVIg), anti-D, and splenectomy.
Main Results:
- Diagnosis of acute ITP is confirmed via blood tests, with a history of viral illness in about half of pediatric cases.
- Corticosteroids are cost-effective but may have slow platelet response and adverse effects.
- Intravenous immunoglobulin (IVIg) offers rapid platelet increase but is expensive with potential infusion reactions; anti-D is a less costly alternative with manageable hemolysis.
Conclusions:
- Effective diagnosis of acute ITP requires a comprehensive approach combining clinical assessment and laboratory findings.
- Treatment selection for acute ITP involves balancing efficacy, cost, and potential adverse effects of therapies like corticosteroids and IVIg.
- Splenectomy is reserved for severe, refractory cases, while other immunomodulatory treatments are under investigation for ITP management.
Abstract:
Medical history, physical examination, and laboratory testing are essential to arriving at the diagnosis of acute immune thrombocytopenic purpura (ITP). A history of recent viral illness occurs in about half of the pediatric patients who present with acute symptoms of ITP. The physical examination is normal except for purpura; a complete blood cell count with a differential white blood cell count can be used to confirm the diagnosis of acute ITP. Treatment decisions for acute ITP remain controversial. Treatment generally is designed to prevent life-threatening complications, such as intracranial hemorrhage, and may include single or combination therapy with corticosteroids, intravenous immunoglobulin (IVIg), anti-D, and splenectomy. Corticosteroids are inexpensive and offer an alluring option, especially in the recent era of cost-containment. The often slow platelet response and the potentially severe adverse effects of corticosteroid therapy are frequently a deterrent. IVIg usually leads to a rapid rise in platelet count; however, IVIg is very expensive and adverse effects associated with its infusion are common and sometimes troublesome. The role of anti-D in acute ITP is still evolving. It is similar to IVIg in platelet response and is considerably less expensive. Some degree of hemolysis, the main adverse reaction with anti-D, is inevitable due to the binding of anti-D antibody to Rh-positive erythrocytes. However, most cases of hemolysis do not require medical intervention. Splenectomy is reserved for refractory thrombocytopenia with life-threatening hemorrhage in acute ITP or after recurrent severe thrombocytopenia in chronic ITP. Other immunomodulatory therapies are also discussed.